

Jean Johnson 5/2/07

Curriculum Vitae
JEAN COAKER JOHNSON, RD, CCRC

Business Address:

National Clinical Research, Inc.
2809 Emerywood Parkway
Suite 140
Richmond, VA 23294
(804) 672-2133 ext.14

EDUCATION

- 1997 Clinical Research Coordinator Certification
- 1979 Dietetic Internship
Henry Ford Hospital
Detroit, MI
- 1978 Completed 25 hours towards MS in Nutrition
Virginia Polytechnic Institute and State University
Blacksburg, VA
- 1974 - 1977 Bachelor of Science Degree in Nutrition
James Madison University
Harrisonburg, VA

PROFESSIONAL EXPERIENCE

- 1992-present Registered Dietitian
Certified Clinical Research Coordinator
National Clinical Research, Inc.
Richmond, VA
- 1984-1992 Mirror Image-A Nutrition Consulting Firm
Richmond, VA
- 1982 - 1992 Camelot Hall Nursing Homes
Richmond, VA
- 1979 - 1982 Clinical Dietitian
Medical College of Virginia Hospitals,
Richmond, VA

PROFESSIONAL AFFILIATIONS

Certified Clinical Research Coordinator
Association of Clinical Research Professionals
American Dietetic Association
Virginia Dietetic Association
Richmond Dietetic Association

CLINICAL RESEARCH EXPERIENCE

Study Coordinator

A double-blind dose-ranging study of BAY w 6228 in doses of 50 mcg, 100 mcg, 200 mcg, 300 mcg once daily compared to placebo, and to lovastatin 40 mg once daily in patients with hypercholesterolemia, Miles Pharmaceutical Division (Protocol 035), Jan93 – Dec93.

Comparison of the safety and efficacy of ACA-147 in patients with high blood cholesterol, Protocol, Wyeth-Ayerst Pharmaceutical, Oct 93-Oct 94.

A study to compare the efficacy and safety of once, twice and three times a day administration of cp-148,623 at daily doses of 180 mg and 600 mg in patients with high blood cholesterol, Pfizer (Protocol 169-103-5017), Jul94 – Feb95.

An assessment of the cost effectiveness study of treating to NCEP goal with atorvastatin as compared to fluvastatin, lovastatin, and simvastatin in patients with CHD and/or peripheral vascular disease, Parke Davis (Protocol 981-69), Feb 95-Jun 96.

An assessment of the cost effectiveness study of treating to NCEP goal with atorvastatin as compared to fluvastatin, lovastatin, and simvastatin in patients with risk factors for CHD, Parke Davis (Protocol 981-70), Feb 95-Jun 96.

A four-year, double-blind, multicenter, placebo-controlled study of the effects of three different doses of calcimar on bone mineral density, stature, and biochemical markers of bone turnover in women with established post menopausal osteoporosis, Corning Besselaar/Rhone Poulenc Rorer (Protocol RG-83853-402), Oct 95-Oct 99.

A multicenter, randomized, parallel group, 8-week comparative dose efficacy and safety study of once daily atorvastatin with that of lovastatin, pravastatin, simvastatin, and fluvastatin in patients with elevated LDL-cholesterol (CURVES), Parke Davis (Protocol 981-86), Sept 95-Nov 96.

A randomized, double blind, placebo-controlled evaluation of Cholestagel in patients with primary hypercholesterolemia, GelTex Pharmaceuticals (Protocol GTC 37-201c), Jul96 - Mar 97.

A randomized, modified double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and the dose-response of a new estradiol matrix transdermal therapeutic system in the prevention of postmenopausal bone loss, Ciba-Geigy Corporation (Protocol 035), Aug 96-Dec 98.

A double-blind, randomized, multi-center, placebo-controlled trial of 0.5 and 1.25 mg of levormeloxifene for the treatment of postmenopausal osteoporosis, NovoNordisk (Protocol LEV/PD/16/USA), Dec97 – Sep01

A double-blind, randomized, multi-center, placebo-controlled trial of levormeloxifene and prempo for the prevention for postmenopausal osteoporosis, NovoNordisk (Protocol LEV/PD/15/USA), Dec97 – Sept01.

Phase II, double-blind placebo-controlled trial of the safety, toleration and efficacy of CP-336, 156 and ralozifene 60 mg/day for the prevention of bone loss in postmenopausal women, Pfizer (Protocol 218-102), Feb98 – Aug01.

